FDA proposes new rare disease framework to accelerate therapy development

During a public hearing, FDA officials outlined a newly proposed rare disease framework aimed at creating a lasting regulatory scheme.

The initiative seeks to speed the development of safe and effective therapies by offering clearer guidance, increasing patient engagement, fostering expert collaboration, and applying innovative scientific approaches.

The effort is coordinated through the FDA's Rare Disease Innovation Hub, which brings together the Centers for Devices and Radiological Health, Biologics Evaluation and Research, and Drug Evaluation and Research under the leadership of Michael Davis. Officials described the plan as a "quantum leap" built from the ground up with input from all stakeholders.